Quick Answer
NEKTAR THERAPEUTICS reported Operating Income Loss of -$140.10 million for the year ending 2025.
- NEKTAR THERAPEUTICS showed a decrease of -33.2% in Operating Income Loss from 2024 to 2025.
- This data is from NEKTAR THERAPEUTICS's annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), NEKTAR THERAPEUTICS's Operating Income Loss has declined by 47.3%.
- Historical annual values: Fiscal year 2025: -$140.10 million | Fiscal year 2024: -$105.20 million | Fiscal year 2023: -$263.68 million | Fiscal year 2022: -$376.17 million | Fiscal year 2021: -$446.10 million | Fiscal year 2020: -$425.11 million | Fiscal year 2019: -$440.04 million | Fiscal year 2018: $687.93 million | Fiscal year 2017: -$59.64 million | Fiscal year 2016: -$112.86 million | Fiscal year 2015: -$29.37 million | Fiscal year 2014: -$16.49 million | Fiscal year 2013: -$120.13 million | Fiscal year 2012: -$141.20 million | Fiscal year 2011: -$123.94 million | Fiscal year 2010: -$28.26 million | Fiscal year 2009: -$95.13 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: